Biased agonism at free-fatty acid receptor-4 (FFA4/GPR120)

Area of Science:

• Pharmacology
• Molecular Biology
• Endocrinology

Background:

• Free-fatty acid receptor-4 (FFA4), also known as GPR120, is activated by various free fatty acids and plays crucial roles in human health.
• FFA4 is involved in releasing incretin hormones (e.g., GLP-1), regulating glucose uptake, and mediating anti-inflammatory responses.
• Its involvement in energy metabolism and inflammation makes FFA4 a significant drug discovery target.

Purpose of the Study:

• To review the concept of biased agonism at FFA4.
• To highlight the selective signaling of FFA4 through distinct pathways, including Gα proteins and β-arrestins.
• To discuss structural elements governing FFA4 interactions and their therapeutic implications.

Main Methods:

• Literature review focusing on FFA4 signaling pathways.
• Analysis of emerging evidence on Gα protein and β-arrestin interactions.
• Examination of structural determinants of FFA4-ligand interactions.

Main Results:

• FFA4 signaling is not limited to Gαq/11 proteins; it also involves other Gα proteins and β-arrestins.
• Distinct signaling pathways mediate different physiological effects of FFA4, such as GLP-1 release and anti-inflammatory actions.
• Understanding FFA4 structural biology is crucial for developing biased agonists.

Conclusions:

• FFA4 exhibits biased agonism, selectively activating different downstream signaling pathways.
• Targeting specific FFA4 pathways offers potential for developing novel therapeutics for metabolic and inflammatory diseases.
• Further research into FFA4 structural elements will enable the design of precise biased agonists.